Prostate Cancer International is a
non-profit for 2012 as rated by Great NonProfits
A new review article in Oncology discusses the potential of multiparametric magnetic resonance imaging (mpMRI) in the diagnosis and management of prostate cancer, and will be useful reading for many advocates and support group leaders. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Diagnosis, imaging, MRI, multiparametric, prognosis | 1 Comment »
According to an article published on the Medscape Oncology web site earlier today, two paper presented at the European Congress of Radiology have provided further evidence of the potential of MRI-guided biopsies in the diagnosis of prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, imaging, magnetic, MRi-guided, resonance | 3 Comments »
According to a media release issued today by Progenics Pharmaceuticals, early clinical studies of two of their investigational products — the imaging agents [123I]-MIP-1072 and [123I]-MIP-1095 — suggest potential of these two agents in enhancement of imaging techniques to identify the exact location of cancer in bone, tissue, and the prostate itself. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: agent, imaging, MIP-1072, MIP-1095, MIP-1404 | Leave a Comment »
Two recent studies are helpful in clarifying the issue of when specific types of magnetic resonance imaging (MRI) meothds may be useful in the diagnosis and prognosis of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: accuracy, diagnopsis, imaging, magnetic resonance, MRI, prognosis, transrectal ultrasound, TRUS, value | 2 Comments »
One of the hardest things to be able to do, currently, in a man with progressive prostate cancer after first- or second-line therapy, is to determine his risk for lymph node-positive prostate cancer or LNPPC (i.e., one of the earliest and more common components of metastatic prostate cancer). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: accuracy, identification, imaging, lymph node, positive, test | 5 Comments »
A report just published on line in Nature Medicine describes the first use of intraoperative, tumor-specific fluorescence imaging to highlight the precise position of small groups of cancer cells in women with ovarian cancer, thereby allowing the surgeon to carefully excise such small groups of cells. … READ MORE …
Filed under: Management, Treatment | Tagged: cells, excision, fluorescence, imaging, surgery, tumor | Leave a Comment »
An article in the June issue of the journal Acta Oncologia discusses the potential of newer types of imaging technology as methods to monitor the progression of disease in men with castrate-resistant prostate cancer (CRPC). … READ MORE -
Filed under: Living with Prostate Cancer, Management | Tagged: castrate-resistant, imaging | Leave a Comment »
With the failure of Combidex (ferumoxtran-10) to achieve FDA approval as an imaging agent for lymph node-positive prostate cancer and the recognized limitations of the ProstaScint (capromab pendetide) scan, there is a widely acknowledged need for a much more specific and accurate prostate cancer imaging agent than anything currently available. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Endocyte, imaging, prostate cancer-specific, Purdue | Leave a Comment »
According to a media release issued on Thursday this week by Molecular Insight Pharmaceuticals, Inc. (MIP), an investigational imaging agent known as Trofex™ (a.k.a, 123I-MIP-1072) may offer a new opportunity to identify the presence of early signs of metastatic prostate cancer in the prostate bed, soft tissues, and bone within 4 hours after injection. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: 123I-MIP-1072, agent, imaging, PMSA, Trofex | 2 Comments »
There are several interesting new publications worth commenting on this morning — all in the evolving research field as opposed to current clinical practice:
Filed under: Drugs in development, Management, Risk, Treatment | Tagged: angiogenesis, calcitriol, cryotherapy, GTI-2040, hybrid, imaging, statin, synergy | Leave a Comment »
It is probably fair to say that readers should expect little in the way of revolutionary new information affecting the management of prostate cancer from this year’s annual meeting of the American Urological Association (AUA). However, … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk, Treatment | Tagged: active surveillance, imaging, Management, screening | 4 Comments »
In today’s new reports we summarize information from recent papers dealing with:
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: apex, biochemical recurrence, biopsy, Diagnosis, dissection, imaging, intrafascial, open, RALP, risk, robot-assisted, surgery, work-up | 1 Comment »
Search for new and
ongoing trials on the
CTAG PCa web site